Suppr超能文献

增殖细胞核抗原表达在肝细胞癌中的预后意义

Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma.

作者信息

Ng I O, Lai E C, Fan S T, Ng M, Chan A S, So M K

机构信息

Department of Pathology, University of Hong Kong, Queen Mary Hospital, Pokfulam.

出版信息

Cancer. 1994 May 1;73(9):2268-74. doi: 10.1002/1097-0142(19940501)73:9<2268::aid-cncr2820730906>3.0.co;2-o.

Abstract

BACKGROUND

Proliferating cell nuclear antigen (PCNA) is a nuclear protein synthesized in G1/S-phase of the cell cycle and therefore is related to cell proliferative activity. In an attempt to evaluate its prognostic significance and clinicopathologic correlation in patients with hepatocellular carcinoma (HCC), the proliferative activity was studied using immunohistochemical staining with monoclonal antibody to PCNA.

METHODS

Seventy-two patients (64 men, 8 women; mean age, 52 years [range, 24-77 years]) having HCC surgically resected were studied. Tumor and nontumor tissues were selected from each case and stained with PCNA antibody. Tumor and nontumor PCNA (T-PCNA and NT-PCNA) scores were assessed by counting the positive staining nuclei per 1000 cells.

RESULTS

The T-PCNA score ranged from 10 to 894 per 1000 cells (mean +/- standard deviation = 333 +/- 263). It was found to be significantly and positively associated with positive margin (P = 0.003), direct liver invasion by tumor (P = 0.021), and venous permeation (P = 0.020), features directly or indirectly related to tumor invasiveness. However, it had no significant association with tumor size, cellular differentiation, or patients' hepatitis B surface antigen (HBsAg) status. When the tumors were stratified into two groups with a T-PCNA score less than or equal to 200 and a T-PCNA score greater than 200, those patients with a T-PCNA score less than or equal to 200 had significantly longer disease-free survival (DFS) and actual survival (AS) rates than those with scores greater than 200 (median DFS and AS, 34.6 and 49.3 months and 7.7 and 19.1 months, respectively; P = 0.019 and 0.035 for DFS and AS, respectively). T-PCNA and NT-PCNA scores had no significant correlation with the HBsAg status of the patients.

CONCLUSIONS

Proliferative activity in HCC, as defined by PCNA immunohistochemical analysis, is significantly related to tumor invasiveness. It is also a potentially valuable prognostic factor in patients with this tumor.

摘要

背景

增殖细胞核抗原(PCNA)是一种在细胞周期的G1/S期合成的核蛋白,因此与细胞增殖活性相关。为了评估其在肝细胞癌(HCC)患者中的预后意义及临床病理相关性,采用抗PCNA单克隆抗体免疫组化染色研究增殖活性。

方法

研究72例接受手术切除的HCC患者(64例男性,8例女性;平均年龄52岁[范围24 - 77岁])。从每个病例中选取肿瘤组织和非肿瘤组织,用PCNA抗体染色。通过计算每1000个细胞中的阳性染色细胞核来评估肿瘤和非肿瘤PCNA(T - PCNA和NT - PCNA)评分。

结果

T - PCNA评分范围为每1000个细胞10至894(均值±标准差 = 333±263)。发现其与手术切缘阳性(P = 0.003)、肿瘤直接侵犯肝脏(P = 0.021)及静脉浸润(P = 0.020)显著正相关,这些特征直接或间接与肿瘤侵袭性相关。然而,它与肿瘤大小、细胞分化或患者的乙肝表面抗原(HBsAg)状态无显著相关性。当将肿瘤分为T - PCNA评分小于或等于200和大于200的两组时,T - PCNA评分小于或等于200的患者无病生存期(DFS)和实际生存期(AS)显著长于评分大于200的患者(DFS和AS的中位数分别为34.6和49.3个月以及7.7和19.1个月;DFS和AS的P值分别为0.019和0.035)。T - PCNA和NT - PCNA评分与患者的HBsAg状态无显著相关性。

结论

通过PCNA免疫组化分析定义的HCC增殖活性与肿瘤侵袭性显著相关。它也是该肿瘤患者潜在的有价值的预后因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验